Literature DB >> 12036854

The role of cytokines in classical Hodgkin lymphoma.

Brian F Skinnider1, Tak W Mak.   

Abstract

The clinical and pathologic features of classical Hodgkin lymphoma (cHL) reflect an abnormal immune response that is thought to be due to the elaboration of a variety of cytokines by the malignant Reed-Sternberg (RS) cells or surrounding tissues. The majority of cHL cases are characterized by expression of tumor necrosis factor receptor (TNFR) family members and their ligands, as well as an unbalanced production of Th2 cytokines and chemokines. Activation of TNFR members results in constitutive activation of nuclear factor-kappa B (NF-kappa B), a transcription factor important for the in vitro and in vivo growth of RS cell lines. The expression of Th2 cytokines and chemokines leads to the reactive infiltrate of eosinophils, Th2 cells, and fibroblasts characteristic of cHL, and can also contribute to a local suppression of Th1 cell-mediated cellular immune response. Another particularly important growth and survival factor for RS cell lines is the Th2 cytokine interleukin 13, which is also commonly expressed by primary RS cells. In approximately 40% of cHL cases, the presence of Epstein-Barr virus influences the Th1/Th2 balance toward the production of Th1 cytokines and chemokines, but this shift is apparently insufficient for the stimulation of an effective antitumor cell-mediated immune response. This review summarizes the current literature on cytokine expression by and activity on RS cell lines and primary cHL tissues, examines cytokine signaling pathways in RS cells, and discusses the role that cytokines play in the specific clinical and pathologic features of cHL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036854     DOI: 10.1182/blood-2002-01-0099

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  115 in total

1.  Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma.

Authors:  Maria Kowalska; Joanna Tajer; Magdalena Chechlinska; Malgorzata Fuksiewicz; Beata Kotowicz; Małgorzata Syczewska; Jan Walewski; Janina Kaminska
Journal:  Tumour Biol       Date:  2012-06-08

Review 2.  Recognizing unusual manifestations of Hodgkin lymphoma.

Authors:  Nicholas A Barber; Philip J Bierman
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

3.  Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma.

Authors:  Alex Reza Gholiha; Peter Hollander; Ingrid Glimelius; Gustaf Hedstrom; Daniel Molin; Henrik Hjalgrim; Karin E Smedby; Jamileh Hashemi; Rose-Marie Amini; Gunilla Enblad
Journal:  Blood Adv       Date:  2021-03-23

4.  The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas.

Authors:  Leon Bernal-Mizrachi; Christine M Lovly; Lee Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-02       Impact factor: 11.205

Review 5.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

6.  Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma.

Authors:  Christoph Renné; Jose Ignacio Martin-Subero; Maren Eickernjäger; Martin-Leo Hansmann; Ralf Küppers; Reiner Siebert; Andreas Bräuninger
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 7.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

Review 8.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

9.  Using haplotype analysis to elucidate significant associations between genes and Hodgkin lymphoma.

Authors:  Anthony M D'Amelio; Claudia Monroy; Randa El-Zein; Carol J Etzel
Journal:  Leuk Res       Date:  2012-08-14       Impact factor: 3.156

10.  Lack of association between IL-4 -588C>T polymorphism and NHL susceptibility.

Authors:  Zihan Sun; Jing Pei; Fengyun Cui; Yanhua Jing; Chengjin Hu
Journal:  Tumour Biol       Date:  2014-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.